Most Read Articles
Yesterday
Exposure to corticosteroids in patients with autoimmune hepatitis (AIH) appears to contribute to increased risks of cataract, diabetes and bone fractures, a study has found. Notably, the fracture risk is elevated at low doses, while the risk of adverse events overall is dose-dependent and is reversible.
6 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 12 Nov 2019
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 4 days ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.

Apalutamide offers similar HRQoL vs ADT alone in nonmetastatic castration-resistant prostate cancer

Christina Lau
12 Apr 2018

Men with nonmetastatic castration-resistant prostate cancer (CRPC) have similar health-related quality of life (HRQoL) with apalutamide given on top of androgen deprivation therapy (ADT) vs ADT alone, according to new data from the SPARTAN (Prostate Androgen Receptor Targeting with ARN-509) trial presented at the European Association of Urology (EAU) 2018 Congress.

In the phase III trial, 1,207 patients with nonmetastatic CRPC who had a prostate-specific antigen (PSA) doubling time of 10 months were randomized in a 2:1 ratio to receive oral apalutamide (240 mg daily) or placebo in addition to ADT (either with a gonadotropin-releasing hormone analogue or surgical castration). [N Engl J Med 2018;378:1408-1418]

After a median follow-up of 20.3 months, apalutamide was associated with a 72 percent reduction in the risk of metastasis and a 2-year extension in metastasis-free survival compared with placebo (median, 40.5 months vs 16.2 months; hazard ratio [HR], 0.28; p<0.0001). These results led to the US FDA’s approval of apalutamide in February 2018 as the first drug for nonmetastatic CRPC.

In the SPARTAN trial, patients’ HRQoL was assessed using self-reported questionnaires, including the Functional Assessment of Cancer Therapy-General (FACT-G), Functional Assessment of Cancer Therapy-Prostate (FACT-P) and EuroQoL Group EQ-5D-3L questionnaires. These questionnaires were completed at baseline, on day 1 of cycles 2–7, cycle 9, cycle 11 and cycle 13, and subsequently every 4 months for the duration of treatment, as well as at 1 year after treatment discontinuation.

At baseline, the mean FACT-G score was 83/108 in the apalutamide arm and 84/108 in the placebo arm, which were comparable to the mean score of adult patients without prostate cancer (81/108).

Analysis showed that mean changes from baseline in FACT-P total score and all subscores were not significantly different between patients receiving apalutamide plus ADT and those receiving placebo plus ADT.

Furthermore, FACT-G scores and other patient-reported scores were maintained in the apalutamide arm.

“In fact, HRQoL was not only maintained in the apalutamide arm – it might be slightly better compared with patients in the placebo arm,” said co-investigator Professor Fred Saad of the University of Montreal in Quebec, Canada.

According to Saad, it was very important to evaluate the patients’ quality of life. “This is because patients with nonmetastatic CRPC are asymptomatic by definition, and treatment with an active agent could lead to a worsening in quality of life,” he explained.

“Our results also suggest that treatment with drugs such as apalutamide should not be delayed for patients with CRPC who are at high risk of metastasis,” Saad added. “Although patients in the placebo arm were treated with apalutamide upon the development of metastasis, the survival curves continued to separate between the two study arms. In other words, they did not do as well as patients who were started on apalutamide early.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Yesterday
Exposure to corticosteroids in patients with autoimmune hepatitis (AIH) appears to contribute to increased risks of cataract, diabetes and bone fractures, a study has found. Notably, the fracture risk is elevated at low doses, while the risk of adverse events overall is dose-dependent and is reversible.
6 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 12 Nov 2019
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 4 days ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.